Impact of multidrug resistance on experimental empyema by Pseudomonas aeruginosa

Respiration

Volumn 82, Issue 1, 2011, Pages 46-53

  Giamarellos Bourboulis, Evangelos J ^a   Tzepi, Ira ^a   Tsovolou, Irini ^a   Spyridaki, Aikaterini ^a   Tsaganos, Thomas ^a   Vaki, Ilia ^a   Kotsaki, Antigone ^a   Polychronopoulos, Vlasios ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

Author keywords

Apoptosis; Empyema; Multidrug resistance; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANATE POTASSIUM PLUS TICARCILLIN; IMIPENEM; INTERLEUKIN 10; INTERLEUKIN 1BETA; MALONALDEHYDE; MEROPENEM; PIPERACILLIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMPYEMA; EXPERIMENTAL RABBIT; GROWTH RATE; MONOCYTE; MULTIDRUG RESISTANCE; NEUTROPHIL; NONHUMAN; PLEURA FLUID; PRIORITY JOURNAL; PROTEIN CONTENT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; BACTERIAL LOAD; CYTOKINES; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EMPYEMA; HUMANS; IMMUNITY, INNATE; LUNG; MALE; MALONDIALDEHYDE; MONOCYTES; NEUTROPHILS; PLEURAL EFFUSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS; SPECIES SPECIFICITY; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS; VIRULENCE;

EID: 79959288664     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000326893     Document Type: Article

References (18)

1. Wilson R, Dowling RB: Lung infections. 3. Pseudomonas aeruginosa and other related species. Thorax 1998;53:213-219.
2. Edis EC, Hatipoglu ON, Yilmam I, Eker A, Tansel O, Sut N: Hospital-acquired pneumonia developed in non-intensive care units. Respiration 2009;78:416-422.
3. Giamarellos-Bourboulis EJ, Plachouras D, Tzivra A, Koussoulas V, Bolanos N, Raftogiannis M, Galani I, Dontas I, Dionyssiou-Asteriou A, Giamarellou H: Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa : an in vitro and in vivo study. Clin Exp Immunol 2004;135:240-244.
4. Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A, Tsaganos T, Kanallakopoulou K, Giamarellou H: Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Intern J Antimicrob Agents 2006;27:476-481. (Pubitemid 43767087)
5. Schreiber T, Swanson PE, Chang KC, Davis CC, Dunne WM, Karl IE, Reinhart K, Hotchkiss RS: Both Gram-negative and Gram-positive experimental pneumonia induce profound lymphocyte but not respiratory epithelial cell apoptosis. Shock 2006;26:271-276.
6. Usher LR, Lawson RA, Geary I, Taylor CJ, Bingle CD, Taylor GW, Whyte MK: Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: a potential mechanism of persistent infection. J Immunol 2002;168:1861-1868.
7. El Solh AA, Akinnusi ME, Wiener-Kronish JP, Lynch SV, Pineda LA, Szarpa K: Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am J Respir Crit Care Med 2008;178:513-519.
8. Borges VM, Vandivier RW, McPhillips KA, Kench JA, Morimoto K, Groshong SD, Richens TR, Graham BB, Muldrow AM, Van Heule L, Henson PM, Janssen WJ: TNFalpha inhibits apoptotic cell clearance in the lung, exacerbating acute inflammation. Am J Physiol Lung Cell Mol Physiol 2009;297:L586-L595.
9. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing. 15th International Supplement. Wayne, CLSI, 2005, vol 25, pp 34-65.
10. Strahilevitz J, Lev A, Levi I, Fridmann E, Rubistein E: Experimental pneumococcal pleural empyema model: the effect of moxifloxacin. J Antimicrob Chemother 2003;51:665-669. (Pubitemid 36336161)
11. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V, Mouktaroudi M, Perrea D, Karayannacos P, Giamarellou H: Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa . Antimicrob Agents Chemother 2004;48:93-99. (Pubitemid 38040182)
12. Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Antonopoulou A, Adamis T, Sabracos L, Giamarellou H: Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae . J Antimicrob Chemother 2006;57:937-944.
13. Agarwal R, Chase SD: Rapid, fluorometricliquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr 2002;775:121-126. (Pubitemid 34717929)
14. Gregory AD, Hogue LA, Ferkol TW, Link DC: Regulation of systemic and local neutrophil responses by G-CSF during pulmonary Pseudomonas aeruginosa infection. Blood 2007;109:3235-3243. (Pubitemid 46572508)
15. Schultz MJ: Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2005;54:21-28.
16. Le Berre R, Faure K, Fauvel H, Gosset P, Epaulard O, Toussaint B, Polack B, Nowak E, Viget NB, Kipnis E, Guery BP: Apoptosis inhibition in P. aeruginosa -induced lung injury influences lung fluid balance. Intensive Care Med 2004;30:1204-1211.
17. Hotchkiss R, Dunne W, Swanson P, Davis CG, Tinsley KW, Chang KC, Buchman TG, Karl IE: Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science 2001;294:1783a-1783b.
18. Giamarellos-Bourboulis EJ, Koussoulas V, Panagou C, Adamis T, Baziaka F, Skiadas I, Perrea D, Dionyssiou-Asteriou A, Giamarellou H: Experimental sepsis using Pseudomonas aeruginosa: the significance of multidrug resistance. Int J Antimicrob Agents 2004;24:357-361.